Skip to main content

Table 3 Previous antimicrobial therapy within 1 month before SM bacteremia onset

From: Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteremia: a retrospective study

Antibiotics

Total

(N = 55)

Hemorrhagic pneumonia(N = 27)

Non-hemorrhagic pneumonia (N = 28)

P-value

Carbapenems, No. (%)

46 (83.6)

23 (85.2)

23 (82.1)

1.000

aAnti-MRSAs, No. (%)

38 (69.1)

16 (59.3)

22 (78.6)

0.121

Aminoglycoside, No. (%)

5 (9.1)

3 (11.1)

2 (7.1)

0.966

Tigecycline, No. (%)

23 (41.8)

16 (59.3)

7 (25.0)

0.010

Fluoroquinolones, No. (%)

11 (20.0)

6 (22.2)

5 (17.9)

0.686

TMP-SMX, No. (%)

3 (5.5)

0 (0.0)

3 (10.7)

0.236

Piperacillin/tazobactam, No. (%)

15 (27.3)

10 (37.0)

5 (17.9)

0.110

Cefoperazone/sulbactam, No. (%)

30 (54.5)

14 (51.9)

16 (57.1)

0.694

bAnti-fungles, No. (%)

45 (81.8)

20 (74.1)

25 (89.3)

0.266

  1. aAnti-MRSAs included glycopeptides, linezolid, and daptomycin
  2. bAnti-fungles included fluconazole, voriconazole, posaconazole, caspofungin and micafungin